EchoGen

Withdrawn

This medicine's authorisation has been withdrawn

dodecafluoropentane

Overview

The marketing authorisation for EchoGen has been withdrawn at the request of the marketing authorisation holder.

Product information

22/01/2001

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

• summary of product characteristics (annex I);
• manufacturing authorisation holder responsible for batch release (annex IIA);
• conditions of the marketing authorisation (annex IIB);
• labelling (annex IIIA);
• package leaflet (annex IIIB).

Product details

• Name of medicine:
  EchoGen
• Active substance:
  dodecafluoropentane
• International non-proprietary name (INN) or common name:
  dodecafluoropentane
• Therapeutic area (MeSH):
  Echocardiography
• Anatomical therapeutic chemical (ATC) code:
  V08DA

Pharmacotherapeutic group

Contrast media

Therapeutic indication

EchoGen is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular border delineation with resulting improvement in wall motion visualisation.

EchoGen should only be used in patients where the study without contrast enhancement is inconclusive.

Authorisation details

• EMA product number:
  EMEA/H/C/000149
• Marketing authorisation holder:
  Sonus Pharmaceuticals Ltd.

  Knyvett House; The Causeway; Staines, Middlesex TW18 3BA; United Kingdom

• Marketing authorisation issued:
  17/07/1998